Evidence map›Paper›PMID 40788532›Full record

ArticleACS chemical biology2025

Activation of

Raphael Geißen, Okan Yildirim, Maja Köhn, David A Scheinberg, Derek S Tan

Abstract read
In one paragraph

Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Raphael GeißenChemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.ORCID 0000-0002-9402-0621
Okan YildirimChemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Maja KöhnFaculty of Biology, Institute of Biology III and Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg im Breisgau 79104, Germany.ORCID 0000-0001-8142-3504
David A ScheinbergMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Derek S TanChemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PERALES, MIGUEL-ANGEL · 1985 to 2023
$59.0M
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2M
NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA241894
6 · The paper itself

Abstract

Targeted enzyme-prodrug systems deliver an exogenous enzyme to a disease site to generate active drug locally, thus increasing therapeutic efficacy and decreasing systemic toxicity. The majority of such systems have used bacterial enzymes, which are subject to immune recognition and inactivation or clearance

Indexed as

AmidohydrolasesDipeptidesProdrugsDoxorubicinHumansZidovudine5'-O-succinylzidovudineAmidohydrolasesDipeptidesDoxorubicinpeptide deformylaseProdrugsZidovudine

Identifiers

PMID40788532
PMCPMC12459281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.